Skip to main content

Boehringer Ingelheim Venture Fund — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

60
Companies
$983.2M
Total invested
$19.3M
Avg. check
20
Industries
Biotechnology 19Health Care 10Therapeutics 10Medical 7Life Science 5Medical Device 4+14 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 60
Glox Therapeutics
January 2025

Glox Therapeutics creates precision antibiotics through the use of engineered protein bacteriocins.

Biotechnology · Glasgow$617K Grant
Actym Therapeutics, Inc.
October 2023

Actym Therapeutics is a biotech company that focuses on the discovery and development of novel immuno-oncology therapies to treat cancer.

Biotechnology · Berkeley$25.5M Series A
Centauri Therapeutics
February 2026

Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of life threatening diseases.

Biotechnology · Alderley Park$8.1M Series A
TECregen
January 2026

TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses.

Biotechnology · Basel$12.5M Seed
STRM.BIO
January 2026

STRM.BIO is a biotechnology company that uses extracellular vesicles to deliver gene therapy in a more efficient and practical manner.

Biotechnology · Cambridge$8.0M Seed
smartbax
October 2025

smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria.

Biotechnology · Munich$5.5M Seed
EvlaBio
July 2025

EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs.

Biotechnology · Zürich$24.6M Seed
ArrePath
June 2025

ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.

Biotechnology · PrincetonSeed
Nuevocor
May 2025

Nuevocor operates as a preclinical-stage biotech company.

Biopharma · Singapore$45.0M Series B
HepaRegeniX
April 2025

HepaRegeniX is developing drugs for treating acute and chronic liver diseases.

Biotechnology · Ulm$24.3M Series Unknown
Refoxy Pharma
December 2024

Developer of therapeutic medicines intended to treat age-related diseases and improve healthy longevity.

Manufacturing · Berlin$9.6M Seed
Aignostics
October 2024

Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research.

Artificial Intelligence (AI) · Berlin$34.0M Series B
ImCheck Therapeutics
August 2024

ImCheck Therapeutics designs and develops immunotherapeutic antibodies for the treatment of cancer and autoimmune disease.

Biopharma · Marseille$22.4M Grant
Tacalyx
June 2024

Tacalyx is a biotech company focused on the discovery and development of novel anti-TACA

Biotechnology · Berlin$7.5M Seed
Asgard Therapeutics
March 2024

Asgard Therapeutics is a Biotechnology Company.

Biotechnology · Lund$32.6M Series A
xCures
December 2023

xCures is a SaaS platform that aggregates, organizes and structures EMRs providing multimodal data across all diseases.

Artificial Intelligence (AI) · OaklandConvertible Note
DiogenX
May 2023

DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators.

Biotechnology · Marseille$36.8M Series A
T3 Pharmaceuticals
April 2023

T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments.

Biotechnology · BaselGrant
C-mo Medical Solutions
January 2023

C-mo is the solution providing a complete assessment of cough, adressing key use-cases across the patient management lifecycle.

Health Care · Caparica$760K Seed
Rewind Therapeutics
January 2023

Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.

Biotechnology · AntwerpSeries A
Ruipeng Pet Healthcare
December 2022

Ruipeng Pet Hospital is a Shenzhen-based pet medical and beauty care hospital operator.

Beauty · ShenzhenPrivate Equity
etherna immunotherapies
August 2022

etherna develops mRNA and lipid nanoparticle solutions.

Biotechnology · Niel$38.9M Series B
Perfood
May 2022

Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases.

Personal Health · LübeckSeries Unknown
Optina Diagnostics
January 2022

Optina Diagnostics develops technology for the early detection of disease through the eye.

Artificial Intelligence (AI) · Saint Laurent$2.1M Series A

Where Boehringer Ingelheim Venture Fund invests

Biotechnology19
Health Care10
Therapeutics10
Medical7
Life Science5
Medical Device4

About Boehringer Ingelheim Venture Fund's portfolio

How many companies has Boehringer Ingelheim Venture Fund invested in?

Boehringer Ingelheim Venture Fund has invested in 60 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Boehringer Ingelheim Venture Fund invest in?

Boehringer Ingelheim Venture Fund's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 20 different industry categories.

What is Boehringer Ingelheim Venture Fund's largest investment?

Among tracked funding rounds, Nuevocor received $45.0M in a Series B round. Boehringer Ingelheim Venture Fund's total known invested capital is $983.2M.

What is the average investment size for Boehringer Ingelheim Venture Fund?

Boehringer Ingelheim Venture Fund's average investment size is $19.3M across its portfolio of 60 companies.

What are Boehringer Ingelheim Venture Fund's most recent investments?

Recent Boehringer Ingelheim Venture Fund portfolio additions include Glox Therapeutics, Actym Therapeutics, Inc., Centauri Therapeutics, TECregen, STRM.BIO. These companies were founded in 2020 or later.

Reach the founders behind these 60 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →